Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2003

View Archived Issues

Company Profile: Adventrx Pharmaceuticals

Melatonin as a novel therapy for Alzheimer's disease

Beta-L-2'-Fd4C shows antiviral activity and favorable pharmacokinetics in HBV

Sulphamoylated estrogen derivatives show potential in treating drug-resistant breast cancer

Yamanouchi and GlaxoSmithKline to copromote Vesicare in U.S.

Enrollment opens in phase II trial of Tarceva in malignant glioma

Phase II trial preparations advance for Norwood Immunology technology

Incara selects AEOL-10150 as candidate for ALS

FDA approves Trileptal for children

Paratek claims non-antibacterial tetracyclines for cancer, stroke and lung injury

Novel antibacterial tetracyclines in Paratek development pipeline

Receptor tyrosine kinase inhibitors and their use reported by Theravance

Novel 5-HT2C receptor ligands and their use as antiobesity agents

Novel series of Syk kinase inhibitors covered by Boehringer Ingelheim patent

Phase II DCF-987 trial completes enrollment

Ceregene acquires rights to ALS gene therapy from Salk Institute

ViroPharma acquires maribavir rights from GlaxoSmithKline

FDA Advisory Committee schedules review of Metvix for basal cell carcinoma

SGN-35 selectively targets CD30-positive malignancies in models of Hodgkin's disease

Caprion and AstraZeneca collaborate on pain biomarker research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...